» Articles » PMID: 20160967

In Vitro Models of Pancreatic Cancer for Translational Oncology Research

Overview
Specialties Chemistry
Pharmacology
Date 2010 Feb 18
PMID 20160967
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

BACKGROUND: Pancreatic cancer is a disease of near uniform fatality and the overwhelming majority of patients succumb to their advanced malignancy within a few months of diagnosis. Despite considerable advances in our understanding of molecular mechanisms underlying pancreatic carcinogenesis, this knowledge has not yet been fully translated into clinically available treatment strategies that yield significant improvements in disease free or overall survival. OBJECTIVE: Cell line-based in vitro model systems provide powerful tools to identify potential molecular targets for therapeutic intervention as well as for initial pre-clinical evaluation of novel drug candidates. Here we provide a brief overview of recent literature on cell line-based model systems of pancreatic cancer and their application in the search for novel therapeutics against this vicious disease. CONCLUSION: While in vitro models of pancreatic cancer are of tremendous value for genetic studies and initial functional screenings in drug discovery, they carry several imanent drawbacks and are often poor in predicting therapeutic response in humans. Therefore, in most instances they are successfully exploited to generate hypothesis and identify molecular targets for novel therapeutics, which are subsequently subject to further in-depth characterization using more advanced in vivo model systems and clinical trials.

Citing Articles

Chemoradiotherapy screening in a novel biomimetic polymer based pancreatic cancer model.

Gupta P, Totti S, Perez-Mancera P, Dyke E, Nisbet A, Schettino G RSC Adv. 2022; 9(71):41649-41663.

PMID: 35541584 PMC: 9076463. DOI: 10.1039/c9ra09123h.


Establishment and characterization of a novel ovarian high-grade serous carcinoma cell line-IPO43.

Silva F, Coelho F, Peixoto A, Pinto P, Martins C, Frombach A Cancer Cell Int. 2022; 22(1):175.

PMID: 35501869 PMC: 9063187. DOI: 10.1186/s12935-022-02600-3.


Translation of DNA Damage Response Inhibitors as Chemoradiation Sensitizers From the Laboratory to the Clinic.

Parsels L, Zhang Q, Karnak D, Parsels J, Lam K, Willers H Int J Radiat Oncol Biol Phys. 2021; 111(5):e38-e53.

PMID: 34348175 PMC: 8602768. DOI: 10.1016/j.ijrobp.2021.07.1708.


The Role of Mitochondria in the Chemoresistance of Pancreatic Cancer Cells.

Fu Y, Ricciardiello F, Yang G, Qiu J, Huang H, Xiao J Cells. 2021; 10(3).

PMID: 33669111 PMC: 7996512. DOI: 10.3390/cells10030497.


Beyond just a tight fortress: contribution of stroma to epithelial-mesenchymal transition in pancreatic cancer.

Bulle A, Lim K Signal Transduct Target Ther. 2020; 5(1):249.

PMID: 33122631 PMC: 7596088. DOI: 10.1038/s41392-020-00341-1.


References
1.
Pretlow T, Delmoro C, Dilley G, Spadafora C, Pretlow T . Transplantation of human prostatic carcinoma into nude mice in Matrigel. Cancer Res. 1991; 51(14):3814-7. View

2.
Lahn M, Kloeker S, Berry B . TGF-beta inhibitors for the treatment of cancer. Expert Opin Investig Drugs. 2005; 14(6):629-43. DOI: 10.1517/13543784.14.6.629. View

3.
Mita M, Sankhala K, Abdel-Karim I, Mita A, Giles F . Deforolimus (AP23573) a novel mTOR inhibitor in clinical development. Expert Opin Investig Drugs. 2008; 17(12):1947-54. DOI: 10.1517/13543780802556485. View

4.
Murtaugh L, Leach S . A case of mistaken identity? Nonductal origins of pancreatic "ductal" cancers. Cancer Cell. 2007; 11(3):211-3. DOI: 10.1016/j.ccr.2007.02.020. View

5.
Bendayan M, Duhr M, Gingras D . Studies on pancreatic acinar cells in tissue culture: basal lamina (basement membrane matrix promotes three-dimensional reorganization. Eur J Cell Biol. 1986; 42(1):60-7. View